← Research ProtocolsPT-141 / Bremelanotide
STUDIED EXPOSURE MAP / 2019
PT-141 / Bremelanotide
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / RANDOMIZED PHASE 3OBSTETRICS & GYNECOLOGYSTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
1.75 mg
SC · as needed in the trials
Context: This is a prescription-medicine clinical context. The exposure is reported as study design, not public dosing guidance.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / OBSTETRICS & GYNECOLOGY
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2019
01 / DESIGNTwo phase 3 · randomized · double-blind · placebo-controlled · multicenter trials
02 / POPULATION / MODELPremenopausal women with HSDD
03 / ROUTESubcutaneous · as-needed study administration
04 / TIMEFRAME24 weeks
05 / PRIMARY QUESTIONPrespecified HSDD efficacy and safety endpoints
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Melanocortin-receptor research
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.